ABBV-8E12
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)
Conditions
Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)
Trial Timeline
— → —
NCT ID
NCT03744546About ABBV-8E12
ABBV-8E12 is a pre-clinical stage product being developed by AbbVie for Primary Tauopathy Corticobasal Degeneration Syndrome (CBD). The current trial status is completed. This product is registered under clinical trial identifier NCT03744546. Target conditions include Primary Tauopathy Corticobasal Degeneration Syndrome (CBD).
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03744546 | Pre-clinical | Completed |
| NCT03413319 | Phase 1 | Completed |
Competing Products
20 competing products in Primary Tauopathy Corticobasal Degeneration Syndrome (CBD)